Eczema is extremely common in children. Most the time it is easily treated with topical steroids but on occasion it requires systemic therapies. JAMA Pediatrics Editor Dimitri Christakis, MD, MPH, and JAMA Network Open Editor Frederick Rivara, MD, MPH, discuss the results of a clinical trial of a new monoclonal antibody intended to improve eczema in children that was published in the January 2020 issue of JAMA Pediatrics.
Related:
Are Bacteria Transplants the Future of Eczema Therapy?
Persistence of Childhood Eczema Into Adulthood
Association Between Eczema and Stature in 9 US Population-Based Studies
Management of Atopic Dermatitis
Anti-IgE Medication Lessens Pediatric Atopic Dermatitis Severity